Current Issue
One lab finds that a similar method produces large genetic deletions when performed in mouse embryos.
Levels of active LRRK2 were high even in Parkinson’s patients without a mutation in LRRK2, suggesting that inhibitors of the protein could treat a wider patient population than expected.